Archives

  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10

    • Z-WEHD-FMK: Irreversible Caspase-5 Inhibitor for Inflamma...

    2025-10-25

    Z-WEHD-FMK: Irreversible Caspase-5 Inhibitor for Inflammation & Apoptosis Research

    Executive Summary: Z-WEHD-FMK (CAS 210345-00-9) is a peptide-based, cell-permeable, irreversible inhibitor of inflammatory caspases, primarily caspase-1, -4, and -5, with a molecular weight of 763.77 Da and chemical formula C37H42FN7O10. It interrupts caspase-mediated proteolytic events, notably inhibiting golgin-84 cleavage and Chlamydia-induced Golgi fragmentation in HeLa cells (Padia et al., 2025). Z-WEHD-FMK is insoluble in water, but highly soluble in DMSO (≥46.33 mg/mL) and ethanol (≥26.32 mg/mL, ultrasonic assistance required), and is recommended for storage at -20°C (product page). Typical experimental conditions include an 80 μM, 9-hour treatment in Chlamydia-infected HeLa cells, reducing bacterial load by ~2 logs. This compound is widely used to dissect caspase signaling, apoptosis, pyroptosis, and microbial pathogenesis pathways (see related article).

    Biological Rationale

    Caspases are cysteine aspartate proteases that orchestrate cell death and inflammation via tightly regulated proteolytic cleavage events (Padia et al., 2025). Inflammatory caspases (caspase-1, -4, -5 in humans) are central to the execution of pyroptosis, a pro-inflammatory form of programmed cell death, and the maturation of cytokines such as IL-1β. Disruption of these pathways underpins chronic inflammatory diseases, infectious disease pathogenesis, and certain tumorigenic processes. Z-WEHD-FMK was developed to probe these mechanisms in vitro and in cell-based models, providing a tool to irreversibly inhibit caspase-mediated cleavage events. The ability to block caspase-1 and caspase-4/5 is essential for dissecting canonical and non-canonical inflammasome signaling (more on mechanistic context).

    Mechanism of Action of Z-WEHD-FMK

    Z-WEHD-FMK (Z-Trp-Glu(OMe)-His-Asp(OMe)-FMK) is a tetrapeptide inhibitor conjugated to a fluoromethyl ketone (FMK) warhead, which covalently modifies the active-site cysteine of target caspases. This irreversible modification disables the proteolytic function of caspase-1, caspase-4, and caspase-5 in human cells (Padia et al., 2025). The inhibitor is cell-permeable, enabling intracellular delivery and sustained caspase inhibition. By blocking substrate cleavage, Z-WEHD-FMK disrupts downstream events such as gasdermin D activation, Golgi fragmentation, and inflammatory cytokine processing. Notably, the compound prevents fragmentation of the Golgi apparatus in Chlamydia-infected cells by inhibiting golgin-84 cleavage, a key step in pathogen-driven organelle remodeling (product page).

    Evidence & Benchmarks

    • Z-WEHD-FMK irreversibly inhibits human caspase-1, -4, and -5, as confirmed by in vitro and cell-based cleavage assays (Padia et al., 2025).
    • In HeLa cells infected with Chlamydia trachomatis, 80 μM Z-WEHD-FMK for 9 hours blocks golgin-84 cleavage and reduces bacterial inclusion-forming units by ≈2 log10 (product page).
    • The compound is not soluble in water but dissolves in DMSO (≥46.33 mg/mL) and ethanol (≥26.32 mg/mL with sonication), enabling flexible experimental design (product page).
    • Z-WEHD-FMK does not inhibit murine caspase-11, highlighting species-selectivity and the need for orthologous inhibitors in rodent models (Padia et al., 2025).
    • Pyroptosis induced by caspase-1 activation can be blocked by Z-WEHD-FMK, similar to YVAD inhibitors, confirming its efficacy in canonical inflammasome pathways (Padia et al., 2025).

    For additional mechanistic and translational insights, see this in-depth analysis, which extends the present article by focusing on pyroptosis and Chlamydia pathogenesis beyond classical apoptosis assays.

    Applications, Limits & Misconceptions

    Z-WEHD-FMK is widely used to probe caspase signaling in inflammation research, apoptosis assays, and infectious disease models. Key applications include:

    • Inhibition of canonical and non-canonical inflammasome pathways (caspase-1/-4/-5) in human cell lines.
    • Dissection of cell death modalities, especially pyroptosis, in tumorigenesis and microbial infection contexts (Padia et al., 2025).
    • Prevention of Golgi fragmentation and disruption of pathogen-associated lipid trafficking in Chlamydia-infected cells (product page).
    • Use as a control or comparative agent in caspase inhibition studies alongside other peptide-FMK inhibitors.

    For a strategic perspective on workflow optimization, refer to this resource, which clarifies how Z-WEHD-FMK can be integrated for advanced pyroptosis and Chlamydia research, complementing the present dossier with protocol guidance.

    Common Pitfalls or Misconceptions

    • Species Selectivity: Z-WEHD-FMK does not inhibit murine caspase-11; results in mouse models require alternative inhibitors.
    • Irreversibility: The FMK warhead covalently modifies caspases; effects are not reversible by washout.
    • Solubility Constraints: The compound is insoluble in water; improper solvent use can lead to aggregation or experimental failure.
    • Storage: Solutions are not stable for long-term storage; fresh preparation is recommended to maintain potency.
    • Non-specific Effects at High Concentrations: Off-target protease inhibition may occur at concentrations above recommended ranges.

    Workflow Integration & Parameters

    Preparation: Dissolve Z-WEHD-FMK in DMSO (≥46.33 mg/mL) or ethanol (≥26.32 mg/mL, ultrasonic assistance required). Store solid at -20°C; avoid repeated freeze-thaw cycles. Use freshly prepared solutions for each experiment.

    Typical Protocol: Treat Chlamydia trachomatis-infected HeLa cells with 80 μM Z-WEHD-FMK for 9 hours at 37°C and 5% CO2. For caspase signaling assays, select concentrations between 10–100 μM based on cell type and pathway targeted. Monitor endpoint markers such as golgin-84 cleavage, bacterial inclusion counts, and caspase substrate cleavage by immunoblot or fluorescence assays.

    Controls: Include vehicle-only, DMSO, and/or alternative caspase inhibitors (e.g., YVAD-FMK) to validate specificity. Confirm inhibition by loss of expected caspase substrate cleavage.

    Species Consideration: For murine models, use caspase-11-selective inhibitors as Z-WEHD-FMK is not active against mouse orthologs (Padia et al., 2025).

    Conclusion & Outlook

    Z-WEHD-FMK is a validated, potent, and irreversible caspase-5 inhibitor, enabling precise dissection of human inflammatory and apoptotic pathways. Its application has illuminated mechanisms of Golgi fragmentation, pyroptosis, and pathogen-host interactions. The compound remains an indispensable tool for cell biology and infection research, though species and solubility constraints must be respected. For updated protocols, mechanistic expansions, and strategic guidance, consult this advanced review, which updates the present article with competitive analysis and future directions in caspase-focused translational research.

    For product specifications, protocols, and ordering, see the Z-WEHD-FMK (A1924) product page.